What does China's open policy mean to pharma multinationals?

Multinationals (MNCs) were thrilled by China’s recent policies on opening up the domestic pharmaceutical market to the world, notes The Pharma Letter’s local correspondent, Wang Fangqing, in her latest report from the ChinaBio partnering forum held recently in Suzhou.

Examples include faster approval processes to imported novel drugs, the acceptance of foreign clinical data, and the encouragement to Chinese hospitals to participate in global multi-site clinical studies.

Sophie Sun, head of strategy and transformation China at the German pharma Merck, said at ChinaBio that these new polices will allow MNCs to be more active.